Steve Harr

Steve Harr, MD, is President and Chief Executive Officer of Sana Biotechnology.

Prior to co-founding Sana, Steve served as Chief Financial Officer and Head of Corporate Development for Juno Therapeutics until its acquisition by Celgene in early 2018. He was a member of the Board of Directors of Loxo Oncology prior to its acquisition by Eli Lilly in early 2019. Steve also was a co-founder and member of the Board of Directors of JW Therapeutics, a cell therapy company in China. Prior to joining Juno, Steve was at Morgan Stanley, most recently as Managing Director and Head of Biotechnology Investment Banking and previously as a biotech research analyst and co-head of global healthcare research.

Steve obtained a BA in Economics from College of the Holy Cross and an MD from Johns Hopkins University School of Medicine. He was an Internal Medicine resident at the University of California, San Francisco and performed research at Harvard Medical School and Massachusetts General Hospital.